CN106632158B - The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs - Google Patents

The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs Download PDF

Info

Publication number
CN106632158B
CN106632158B CN201610921359.1A CN201610921359A CN106632158B CN 106632158 B CN106632158 B CN 106632158B CN 201610921359 A CN201610921359 A CN 201610921359A CN 106632158 B CN106632158 B CN 106632158B
Authority
CN
China
Prior art keywords
preparation
formula
deprotection
hydroxyl
silicon substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610921359.1A
Other languages
Chinese (zh)
Other versions
CN106632158A (en
Inventor
明方永
黄金昆
蒲刚
阳建洪
武强
顾先涛
陈钰梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Chengdu Suncadia Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201610921359.1A priority Critical patent/CN106632158B/en
Publication of CN106632158A publication Critical patent/CN106632158A/en
Application granted granted Critical
Publication of CN106632158B publication Critical patent/CN106632158B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to 7 β, the preparation methods of 10 β-dimethoxy -10- deacetylate Baccatine IIIs.Specifically; the method of the present invention is using acetyl group berry mycin as raw material; it is protected by the silicon protecting group on 7 and 13; silicon protecting group on selectively removing 7; then the upper direct alkylation at 7 and 10; the series of steps of the silicon protecting group on 13 is finally removed to prepare bearing taxanes 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs shown as a formula V.

Description

The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs
The application is application No. is 201310381240.6, and the applying date is August in 2013 28, entitled " 7 β, 10 The divisional application of the Chinese patent application of the preparation method of β-dimethoxy -10- deacetylate Baccatine IIIs ".
Technical field
The present invention relates to the field of chemical synthesis, more particularly to one kind 7 β, 10 β-dimethoxy -10- deacetylate berries The preparation method of gibberellin III.
Background technology
Cabazitaxel (trade name：Jevtana it is) to be developed " to promote sexual gland to swash by French Sanofi-Aventis drugmaker Hormone-releasing hormone (GnRH) " acceptor inhibitor class drug is in metastatic hormone refractory mainly for Dinner phase patients with prostate cancer Property prostate cancer second line treatment in first and only one the medicine that significantly existence benefits is provided.And 7 β, 10 β-diformazan Oxy-1 0- deacetylate Baccatine IIIs are exactly a key intermediate for synthesizing Cabazitaxel.
7 β of CN1179116A reports, the synthetic route of 10 β-dimethoxy -10- deacetylate Baccatine IIIs is such as Shown in following scheme 1.The reaction does alkali respectively to C using sodium hydride7And C10On hydroxyl methylate, this is industrial production Bring the danger of potential explosion.
Scheme 1
7 β of CN1270586A reports, the synthetic route of 10 β-dimethoxy -10- deacetylate Baccatine IIIs is such as Shown in following scheme 2.Although the reaction is disposably to C7And C10On hydroxyl methylated and yield is higher, but use The hydrofining of dangerous bigger makees alkali, and the impurity of similar structures is more, not easy purification.
Scheme 2
7 β of patent CN102659721A reports, the synthesis of 10 β-dimethoxy -10- deacetylate Baccatine IIIs Route is as shown in following scheme 3.The reaction through protecting and deprotecting twice, although disposably by C7And C10Hydroxyl methylates, But dangerous sodium hydride has been used to make alkali, and step is long, is readily incorporated impurity.
Scheme 3
Therefore it provides a kind of safe, is suitable for largely preparing 7 β, 10 β-dimethoxy -10- deacetylate berries are red mould The method of plain III will have great importance.
Invention content
It is an object of the invention to overcome the shortcoming in the above method, provide one kind can simply, safely prepare 7 The method of β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs.
To achieve the goals above, 7 β provided by the invention, 10 β-dimethoxy -10- deacetylate Baccatine IIIs Preparation method it is as described below：
1) selective protection that hydroxyl is carried out to compound shown in formula I is obtained such as Formula II compound represented, wherein R is (C1-10Alkyl or C6-10Aryl)3Silylation, preferably trimethyl silicon substrate, triethyl group silicon substrate, triisopropylsilyl, tertiary butyl two Methylsilyl, tert-butyl diphenyl silicon substrate
2) to step 1) be prepared as Formula II compound represented carries out selective deprotection, obtain such as formula III institute The compound shown
3) to step 2) be prepared as formula III compound represented carry out hydroxyl methylation reaction, obtain such as formula IV compounds represented
4) to step 3) be prepared as formula IV compound represented carry out silicon substrate deprotection, obtain shown as a formula V Compound
(C is selected in step 1)1-10Alkyl or C6-10Aryl)3It is corresponding halogenated that it may be selected as protecting group in silylation Object is protection reagent, such as when using triethyl group silicon substrate (TES), t-Butyldimethylsilyl (TBS), trimethyl silicon substrate (TMS), Used protection reagent includes but not limited to TESX, TBSX, TMSX, and wherein X is F, Cl, Br, I.Reaction in step 1) is molten Agent is selected from pyridine, N,N-dimethylformamide；Reaction temperature is from 0~120 DEG C.
In a preferred embodiment of the invention, the reagent in step 2) used in Deprotection be selected from hydrofluoric acid pyridiniujm, Hydrofluoric acid triethylamine salt, tetrabutyl amine fluoride, hydrogen chloride, hydrogen bromide, preferably hydrofluoric acid triethylamine salt；Deprotection in step 2) Reaction dissolvent used is selected from dichloromethane, chloroform, ethyl acetate, methyl tertiary butyl ether(MTBE), toluene, preferably dichloromethane.
In a preferred embodiment of the invention, in step 3) using iodomethane or dimethyl suflfate methylating as hydroxyl Reagent, preferably iodomethane；Methylating for hydroxyl carries out under nitrogen protection in step 3)；Reaction dissolvent in step (3) is selected from N,N-dimethylformamide, DMAC N,N' dimethyl acetamide, tetrahydrofuran, 2- methyltetrahydrofurans.
In a preferred embodiment of the invention, step 3) carries out in the presence of alkali, and the alkali is selected from sodium methoxide, ethyl alcohol Sodium, potassium tert-butoxide, sodium tert-butoxide, lithium diisopropyl amido, diisopropyl amido sodium, diisopropyl amido potassium, the preferably tert-butyl alcohol Potassium.
Solvent used in reaction is selected from N,N-dimethylformamide, DMAC N,N' dimethyl acetamide, tetrahydrochysene furan in step (4) It mutters, 2- methyltetrahydrofurans.
In a particularly preferred embodiment of the present invention, the present invention provides 7 β of one kind, 10 β-dimethoxys- The preparation method of 10- deacetylate Baccatine IIIs comprising following steps：
Step (1)：By mass volume ratio (10- 10-deacetylate-baccaIII IIIs (i.e. 10-DAB):Pyridine=1:10~20) Reactant is weighed, 10-DAB is dissolved in pyridine.By 10-DAB：Silylation molar ratio (10-DAB:Silylation reagent=1:2 ~20) silylation reagent is added dropwise, 16h is stirred to react at a temperature of 20 DEG C, then rises to 110 DEG C of 1.5~2h of reaction；Decompression is steamed It evaporates, after removing most of pyridine, is diluted with methyl tertiary butyl ether(MTBE)；It is washed with the 1mol/L dilute hydrochloric acid of 0.5~3 times of reactant volume Wash reactant 1~2 time, then with the water washing reactant of 2~3 times of reactant volumes, collect organic phase, be concentrated into original volume~ 1/10, petroleum ether is added, crystallization obtains white product 1 (Formula II compound).
Step (2)：The white product 1 obtained by step (1) is taken, by mass volume ratio 1:10~100 are dissolved in organic solvent In.(white product 1 in molar ratio:Organic salt or inorganic acid=1:1~2) organic salt or inorganic acid is added dropwise, in 20 DEG C of temperature Under be stirred to react 16h；With the saturated sodium bicarbonate washing reaction object of 2~3 times of reactant volumes, organic phase is collected, is concentrated into Original volume~1/10, is added petroleum ether, and crystallization obtains white product 2 (formula III compound).
Step (3)：The white product 2 obtained by step (2) is taken, by mass volume ratio (white product 2:Organic solvent:Iodine first Alkane=1:2.5:10) it is dissolved in the in the mixed solvent of organic solvent and iodomethane, in molar ratio (white product 2:Alkali=1:1~ 3) alkali is added dropwise, 0.5~2h is stirred to react at a temperature of 0 DEG C；Reaction is quenched with glacial acetic acid；Vacuum distillation removes organic solvent And iodomethane；Chromatographic column is crossed, white product 3 (formula IV compound) is obtained.
Step (4)：The white product 3 obtained by step (3) is taken, by mass volume ratio (white product 3:Organic solvent=1: 10~20) it is dissolved in organic solvent, in molar ratio (white product 3:Tetrabutyl amine fluoride=1:1~2) reaction solution is added, It is stirred to react 2~4h at a temperature of 20 DEG C；Vacuum distillation removes organic solvent；With the water and two of 2~3 times of reactant volumes The mixed solvent of chloromethanes is beaten, and obtains 7 β, 10 β-dimethoxy -10- deacetylate Baccatine III crude products, then with four Hydrogen furans is beaten to obtain sterling.
The present invention has the following advantages：Compared with existing 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs Preparation method, the present invention do not use extremely inflammable and explosive highly basic sodium hydride and hydrofining, keeps production more safe and reliable.
Specific implementation mode
The present invention is explained in detail below with reference to specific example, so that those skilled in the art are more fully understood The present invention.Specific embodiment is only used to illustrate the technical scheme of the present invention, and does not limit the present invention in any way.
Embodiment 1：The conjunction of 7 β, 13 β-bis- (triethyl group silicon substrate) -10- deacetylate Baccatine IIIs (compound II) At
10-DAB (50g, 92mmol) is dissolved in anhydrous pyridine (100ml), under nitrogen protection, 0 DEG C of addition triethyl group Chlorosilane (40ml) is warmed to room temperature reaction 16h, so that reaction mixture is warming up to 110 DEG C, chlorotriethyl silane is then added Reaction mixture after being reacted 2 hours at about 110 DEG C, is dropped to room temperature, water (300ml) is added and dilutes, with methyl- tert fourth by (40ml) Base ether (100ml) extracts, and TLC detects water layer without product.Organic layer is washed with the hydrochloric acid (100ml) of 1mol/L, water (100ml × 2) it washs, sodium sulphate drying, filtering is concentrated under reduced pressure into original volume about 1/10, and petroleum ether (40ml) is added and crystallizes, it is solid to collect white Body obtains 28.6g, yield：40%.
1H-NMR(400MHz；Deuterochloroform)：δ (ppm) 0.55 and 0.68 (2mts, the CH in ethyl2)；0.94 and 1.03 (2t, 9H, the CH in ethyl3)；1.08 (s, 3H, CH3)；1.17 (s, 3H, CH3)；1.58 (s, 1H, OH, 1)；1.73 (S, 3H, CH3) 1.91 and 2.57 (2mts, 1H, CH2H6)；2.04 (s, 3H, CH3)；2.12 and 2.23 (2dd, J=16 and 9,1H, CH2 14)；2.30 (s, 3H, COCH3)；3.88 (d, J=7,1H, H3)；4.16 and 4.32 (2d, J=8.5,1H, CH220)；4.27 (d, J=1,1H, OH 10)；4.40 (dd, J=11 and 7,1H, H7)；4.95 (wide d, J=10,1H, H5)；4.95 (m, 1H, H13)；5.16 (d, J=1,1H, H10)；5.60 (d, J=7,1H, H2)；7.46 (t, 2H, J=7.5, CH OCOC6H5Meta position)； 7.60 (1H, t, J=7.5, CH OCOC6H5Contraposition)；8.09 (1H, d, J=7.5, CH OCOC6H5Ortho position).
Embodiment 2：The synthesis of 13 β-triethyl group silicon substrate -10- deacetylate Baccatine IIIs (compound III)
By 7 β, 13 β-bis- (triethyl group silicon substrate) -10- deacetylates Baccatine IIIs (10g, 13mol) are dissolved in dichloromethane In alkane (100ml), triethylamine hydrofluoride (80ml) is added at room temperature, stirs 16h at room temperature, TLC detection raw materials have reacted Entirely, water (100ml × 3) is added to wash, saturated sodium bicarbonate (100ml) washing, water (100ml) washing, sodium sulphate drying, mistake Filter is concentrated under reduced pressure into original volume about 1/10, and petroleum ether (40ml) is added and crystallizes, and collects white solid and obtains 6.5g, yield：76%, Content 96%.
1H-NMR(400MHz；Deuterochloroform)：δ (ppm) 0.63~0.70 (6H, m, CH2Ethyl)；0.99~1.04 (9H, T, J=8.0, CH3Ethyl)；1.09 (3H, s, CH3)；1.16 (3H, s, CH3)；1.45~1.47 (1H, d, J=7.6, OH 7)； 1.60 (1H, s, OH 1)；1.74 (3H, s, CH3)；1.79~1.86 and 2.55~2.63 (1H, 2m, CH2H6)；2.03 (3H, s, CH3)；2.09~2.16 and 2.21~2.27 (1H, 2dd, J=8.8/15.2, CH214)；2.29 (3H, s, CH3, COCH3)； 3.93~3.95 (1H, d, J=6.8, CH H3)；4.16~4.18 and 4.31~4.33 (1H, 2d, J=8.4, CH220)； 4.19~4.20 (1H, d, J=1.6, OH10)；4.24~4.29 (1H, m, CH H7)；4.93~5.00 (2H, m, CH H5 and 13)；5.23~5.24 (1H, d, J=1.6, CH H10)；5.63~5.65 (1H, d, J=7.2, CH H2)；7.46~7.50 (2H, t, J=7.8, CH OCOC6H5Meta position)；7.59~7.63 (1H, t, J=7.4, CH OCOC6H5Contraposition)；8.08~8.10 (1H, d, J=7.2, CH OCOC6H5Ortho position).
Embodiment 3：13 β-triethyl groups silicon substrate -7 β, 10 β-dimethoxy -10- deacetylate Baccatine III (chemical combination Object IV) synthesis
13 β-triethyl group silicon substrate -10- deacetylates Baccatine IIIs (10g, 15.2mol) are dissolved in tetrahydrofuran In (20ml), be added iodomethane (50ml), reaction solution is cooled to 0 DEG C, under nitrogen protection be added potassium tert-butoxide (5.1mg, 45.6mmol), the reaction about 1h at 0 DEG C is finished, TLC detects raw material, and the reaction was complete, glacial acetic acid (2ml) is added, reaction is quenched, depressurize Distillation removes tetrahydrofuran and iodomethane, dissolves concentrate, water (20ml) washing, saturated sodium bicarbonate with isopropyl ether (40ml) (20ml) is washed, water (20ml) washing, anhydrous sodium sulfate drying, and crude product is concentrated under reduced pressure to obtain, and crude product is directly used in down in filtering Step reaction.
1H-NMR(400MHz；Deuterated dimethyl sulfoxide)：δ (ppm) 0.63~0.74 (6H, m, CH2Ethyl)；1.00~1.05 (9H, t, J=8.4, CH3Ethyl)；1.15 (3H, s, CH3)；1.17 (3H, s, CH3)；1.70 (3H, s, CH3)；1.73~1.81 With 2.67~2.74 (1H, 2m, CH26)；2.06 (3H, s, CH3)；2.11~2.24 (2H, m, CH214)；2.30 (3H, s, CH3, COCH3)；3.31 (3H, s, OCH3)；3.46 (3H, s, OCH3)；3.83~3.85 (1H, d, J=6.8, CH 3)；3.90~ 3.95 (1H, dd, J=6.4/10.4, CH 7)；4.13~4.16 and 4.29~4.32 (1H, 2d, J=8.4, CH220)；4.83 (1H, s, CH 10)；4.95~5.02 (2H, m, CH 5 and 13)；5.58~5.60 (1H, d, J=7.2, CH 2)；7.45~ 7.49 (2H, t, J=8.0, CH OCOC6H5Meta position)；7.58~7.62 (1H, t, J=7.2, CH OCOC6H5Contraposition)；8.08~ 8.10 (1H, d, J=7.2, CH OCOC6H5Ortho position).
Embodiment 4：The synthesis of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs (compound V)
Crude product (10g) obtained by upper step is directly dissolved in tetrahydrofuran (40ml), tetrabutyl amine fluoride (3.6g) is added. 3h is stirred at room temperature, TLC detects raw material, and the reaction was complete, and vacuum distillation removes tetrahydrofuran, and water (20ml), dichloromethane is added (10ml), is stirred overnight at room temperature.White solid is collected in filtering, and white solid is suspended in tetrahydrofuran (10ml) 2h that flows back, It is stored at room temperature overnight.Filtering, collects white solid, and vacuum drying obtains solid 6g, two step yields：70%, purity：96%.
1H-NMR(400MHz；Deuterochloroform)：δ (ppm) 0.94 (6H, s, CH3)；1.46~1.50 and 2.63~2.71 (1H, 2m, CH26)；1.52 (3H, s, CH3)；1.98 (3H, s, CH3)；2.16~2.18 (2H, m, CH214)；2.20 (3H, s, CH3, COCH3)；3.22 (3H, s, OCH3)；3.30 (3H, s, OCH3)；3.74~3.77 (1H, d, J=6.8, CH 3)；3.79~ 3.84 (1H, dd, J=6.4/10.0, CH 7)；4.01~4.06 (2H, dd, J=8.4/11.6, CH220)；4.37 (1H, s, OH 1)；4.65~4.66 (1H, m, CH 13)；4.75 (1H, s, CH 10)；4.96~4.98 (1H, d, J=9.2, CH 5)； 5.27~5.29 (1H, d, J=4.4, OH 13)；5.37~5.39 (1H, d, J=7.2, CH 2)；7.54~7.58 (2H, t, J =7.2, CH OCOC6H5Meta position)；7.64~7.68 (1H, t, J=7.6, CH OCOC6H5Contraposition)；8.00~8.03 (1H, d, J =7.6, CH OCOC6H5Ortho position).
Due to describing the present invention according to its specific embodiment, certain modifications and equivalent variations are for being proficient in this neck The technical staff in domain is obvious and is included within the scope of the invention.

Claims (12)

1. a kind of method preparing Cabazitaxel, including following preparation 7 β, 10 β-dimethoxy -10- deacetylate berries are red mould The step of plain III：
1) selective protection that hydroxyl is carried out to compound shown in formula I, obtains such as Formula II compound represented, and wherein R is (C1-10Alkyl or C6-10Aryl)3Silylation,
2) to step 1) be prepared as Formula II compound represented carries out selective deprotection, obtain as shown in formula III Compound
3) to step 2) be prepared as formula III compound represented carry out hydroxyl methylation reaction, obtain such as formula IV institute The compound shown
4) to step 3) be prepared as formula IV compound represented carry out silicon substrate deprotection, obtain chemical combination shown as a formula V Object
2. preparation method according to claim 1, it is characterised in that R is selected from trimethyl silicon substrate, triethyl group silicon substrate, three isopropyls Base silicon substrate, t-Butyldimethylsilyl.
3. preparation method according to claim 1, which is characterized in that the reaction dissolvent in step 1) is selected from pyridine, N, N- Dimethylformamide；Reaction temperature is from 0~120 DEG C.
4. preparation method according to claim 1, which is characterized in that the reagent in step 2) used in Deprotection is selected from hydrogen Fluoric acid pyridiniujm, hydrofluoric acid triethylamine salt, tetrabutyl amine fluoride, hydrogen chloride, hydrogen bromide.
5. preparation method according to claim 1, which is characterized in that the reagent in step 2) used in Deprotection is hydrogen fluorine Triethylenetetraminehexaacetic acid amine salt.
6. preparation method according to claim 1, which is characterized in that the reaction dissolvent choosing in step 2) used in Deprotection From dichloromethane, chloroform, ethyl acetate, methyl tertiary butyl ether(MTBE), toluene.
7. preparation method according to claim 1, which is characterized in that the reaction dissolvent in step 2) used in Deprotection is Dichloromethane.
8. preparation method according to claim 1, which is characterized in that in step 3) using iodomethane or dimethyl suflfate as The methylating reagent of hydroxyl.
9. according to claim 1 the preparation method, which is characterized in that using iodomethane as the methyl of hydroxyl in step 3) Change reagent.
10. preparation method according to claim 1, which is characterized in that hydroxyl methylates in nitrogen protection in step 3) Lower progress；Reaction dissolvent is selected from N,N-dimethylformamide, DMAC N,N' dimethyl acetamide, tetrahydrofuran, 2- methyltetrahydrofurans.
11. preparation method according to claim 1, which is characterized in that step 3) carries out in the presence of alkali, the alkali choosing From potassium tert-butoxide, sodium tert-butoxide, sodium methoxide, sodium ethoxide, lithium diisopropyl amido, diisopropyl amido sodium, diisopropyl amido Potassium.
12. preparation method according to claim 11, wherein the alkali is potassium tert-butoxide.
CN201610921359.1A 2013-08-28 2013-08-28 The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs Active CN106632158B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610921359.1A CN106632158B (en) 2013-08-28 2013-08-28 The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310381240.6A CN104418826B (en) 2013-08-28 2013-08-28 7 β, the preparation method of the deacetylate Baccatine III of 10 β dimethoxys 10
CN201610921359.1A CN106632158B (en) 2013-08-28 2013-08-28 The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201310381240.6A Division CN104418826B (en) 2013-08-28 2013-08-28 7 β, the preparation method of the deacetylate Baccatine III of 10 β dimethoxys 10

Publications (2)

Publication Number Publication Date
CN106632158A CN106632158A (en) 2017-05-10
CN106632158B true CN106632158B (en) 2018-11-06

Family

ID=52969029

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610921359.1A Active CN106632158B (en) 2013-08-28 2013-08-28 The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs
CN201310381240.6A Active CN104418826B (en) 2013-08-28 2013-08-28 7 β, the preparation method of the deacetylate Baccatine III of 10 β dimethoxys 10

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310381240.6A Active CN104418826B (en) 2013-08-28 2013-08-28 7 β, the preparation method of the deacetylate Baccatine III of 10 β dimethoxys 10

Country Status (1)

Country Link
CN (2) CN106632158B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632158B (en) * 2013-08-28 2018-11-06 江苏恒瑞医药股份有限公司 The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516281A (en) * 2011-10-20 2012-06-27 江苏红豆杉生物科技有限公司 10-deacetylbaccatin III and method for methoxylation of its derivative
CN102659721A (en) * 2012-04-19 2012-09-12 信泰制药（苏州）有限公司 Synthetic method of cabazitaxel
WO2013069027A1 (en) * 2011-09-26 2013-05-16 Fresenius Kabi Oncology Ltd. Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation
CN104418826B (en) * 2013-08-28 2017-06-30 江苏恒瑞医药股份有限公司 7 β, the preparation method of the deacetylate Baccatine III of 10 β dimethoxys 10

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
FR2771092B1 (en) * 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF DERIVATIVES OF THE TAXOID CLASS
US20010041803A1 (en) * 2000-03-21 2001-11-15 Kasitu Gertrude C. Conversion of 9-dihydro-13-acetylbaccatin III to baccatin III and 10-deacetyl baccatin III
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
WO2012142117A1 (en) * 2011-04-12 2012-10-18 Plus Chemicals Sa Solid state forms of cabazitaxel and processes for preparation thereof
CN102285947B (en) * 2011-06-17 2014-12-03 常州大学 Method for synthesizing cabazitaxel
CN102336726B (en) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 Method for preparing cabazitaxel
US20130090484A1 (en) * 2011-10-11 2013-04-11 Scinopharm Taiwan Ltd. Process for making an intermediate of cabazitaxel
CN102408397B (en) * 2011-10-19 2014-08-20 上海贝美医药科技有限公司 New taxane derivative and preparation method thereof
WO2013072766A2 (en) * 2011-10-31 2013-05-23 Scinopharm Taiwan, Ltd. Process for cabazitaxel and intermediates thereof
CN102952102B (en) * 2012-07-27 2015-04-22 江苏奥赛康药业股份有限公司 Compound, preparation method thereof and application of compound in preparation of cabazitaxel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013069027A1 (en) * 2011-09-26 2013-05-16 Fresenius Kabi Oncology Ltd. Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation
CN102516281A (en) * 2011-10-20 2012-06-27 江苏红豆杉生物科技有限公司 10-deacetylbaccatin III and method for methoxylation of its derivative
CN102659721A (en) * 2012-04-19 2012-09-12 信泰制药（苏州）有限公司 Synthetic method of cabazitaxel
CN104418826B (en) * 2013-08-28 2017-06-30 江苏恒瑞医药股份有限公司 7 β, the preparation method of the deacetylate Baccatine III of 10 β dimethoxys 10

Also Published As

Publication number Publication date
CN104418826A (en) 2015-03-18
CN106632158A (en) 2017-05-10
CN104418826B (en) 2017-06-30

Similar Documents

Publication Publication Date Title
CN102653533B (en) Total synthesis method of mangostin
CN102432632A (en) Method for preparing (3R,4R)-3-[(1R)tert-butyl-dimethyl-silyloxyethyl]-4-acetoxyl-2-azetidinone
WO2009099868A1 (en) Process for the preparation of (-) -delta 9-tetrahydrocannabinol
JP2017533973A (en) Processes and intermediates for preparing α, ω-dicarboxylic acid-terminated dialkane ethers
CN102516281B (en) 10-deacetylbaccatin III and method for methoxylation of its derivative
JP5646706B2 (en) Method for producing C-glycoside derivative
CN106632158B (en) The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs
WO2020108146A1 (en) Preparation method for lepimectin, and intermediate thereof
CN106749335B (en) A kind of preparation method and application of halogenated oxygen cephalo-type intermediate
CN106565467B (en) A kind of preparation method of antiallergic bilastine intermediate
CN111170893B (en) Lefamulin intermediate compound and application thereof in preparation of Lefamulin
KR102513651B1 (en) Method for producing ether compound
CN103012181B (en) Method for compounding caffeoyl dopamine
CN106632393B (en) The preparation method for the treatment of tuberculosis drug candidate PA-824
CN104945458B (en) A kind of synthetic method of progesterone
CN107235853A (en) It is a kind of to be used to prepare Canton love-pea vine A prime and its synthetic method of isomers
CN110407830A (en) A method of synthesis N- aryl phenothiazine compound
CN104860908B (en) Method for compounding BNC 105
JP5265144B2 (en) Novel process for producing 3-O-substituted-catechin derivatives
CN104387435B (en) Compound and preparation method and application thereof
CN112778089B (en) New synthetic method of 4, 4-trifluoro-1-butanol and homologs thereof
CN108314689A (en) 4,11- diacyl bergenin derivative synthetic methods
CN102241612B (en) Synthetic method of compound 2-cyclopropyl-1-(2-fluorophenyl)-2-carbonyl ethyl p-methylbenzensulfonate
CN101880285A (en) Method for synthetizing allyl-substituted camptothecin compound
CN105669486B (en) A kind of preparation method and applications of the diaryl benzyl amine derivative of N acyl groups 2,6

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant